Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: Initial COVID-19 infection prior to Paxlovid treatment; This spontaneous case was reported by an other health care professional and describes the occurrence of COVID-19 (Initial COVID-19 infection prior to Paxlovid treatment) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 939904) for COVID-19 vaccination.     Concurrent medical conditions included Allergy.    On 24-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In May 2022, the patient experienced COVID-19 (Initial COVID-19 infection prior to Paxlovid treatment). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 13-May-2022 to 18-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Initial COVID-19 infection prior to Paxlovid treatment) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: positive (Positive) Positive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided. patient was not other medications/products within 2 weeks of starting COVID-19 treatment. Patient had relapse of covid 5 days after finishing paxlovid. Became symptomatic again and tested positive again on antigen test on 22-May-2022.  Treatment medication information was not provided.  Company Comment:  This is a spontaneous case concerning a 47-year-old female patient with no relevant medical history reported, who experienced the unexpected non-serious adverse event of special interest COVID-19, described as initial COVID-19 infection prior to Paxlovid treatment, which occurred approximately 7 months after receiving a dose of mRNA-1273 as the third dose of COVID-19 vaccine (no information disclosed on previous COVID-19 vaccinations). Patient was given a six-day-course of Paxlovid treatment for the initial COVID-19 infection. However, four days after the treatment with Paxlovid, patient became symptomatic again, then tested positive for COVID-19 antigen. Outcome of the event for the initial COVID-19 infection was unknown. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 47-year-old female patient with no relevant medical history reported, who experienced the unexpected non-serious adverse event of special interest COVID-19, described as initial COVID-19 infection prior to Paxlovid treatment, which occurred approximately 7 months after receiving a dose of mRNA-1273 as the third dose of COVID-19 vaccine (no information disclosed on previous COVID-19 vaccinations). Patient was given a six-day-course of Paxlovid treatment for the initial COVID-19 infection. However, four days after the treatment with Paxlovid, patient became symptomatic again, then tested positive for COVID-19 antigen. Outcome of the event for the initial COVID-19 infection was unknown. The benefit-risk relationship of mRNA-1273 is not affected by this report.